CSNK1A1 and lymphoma: Although experiments with the CK1α G40N mutant have been performed previously (25–28), the mechanisms underlying the anti-lymphoma activity and CK1α degradation have not been analyzed; therefore, this study is of great significance in demonstrating the potential of a CK1α-degrading agent as an anticancer drug.